Elamipretide

Elamipretide API

Elamipretide is a mitochondria-targeted tetrapeptide developed to treat diseases caused by mitochondrial dysfunction, including primary mitochondrial myopathy, Barth syndrome, and heart failure.

Mechanism & Research:
Elamipretide selectively targets cardiolipin in the inner mitochondrial membrane, improving:
Mitochondrial bioenergetics
ATP production
Cellular respiration and organ function

It has shown potential to restore mitochondrial structure, reduce oxidative stress, and improve muscle and cardiac performance in both clinical and preclinical studies.